Claris Lifesciences to buy-back 14.49% stake from shareholders for Rs 231.25 crore

21 Mar 2014 Evaluate

Claris Lifesciences will buy-back shares aggregating 14.49% of its total equity capital from shareholders for a total of Rs 231.25 crore. The company will buy-back up to 92.5 lakh shares of face value Rs 10 each at a price of Rs 250. As on February 1, 2014 the promoter and promoter group had a holding of 60.21% stake in the company.

The buy-back through tender offer route gives an option to all the equity shareholders, including the promoter shareholders, to receive the surplus cash by participating in it. The process is being implemented through the tender offer route and would involve allocation of 15% of the outlay to small shareholders.

Claris Lifesciences is one of the few injectables companies in India to have its own front end in the US, the company markets its products through its wholly owned subsidiary Claris Lifesciences Inc. The company now has 11 ANDAs approved and has a total filing of 32 ANDAs.

Peers
Company Name CMP
Adani Enterprises 3079.90
Redington 222.55
Amrapali Industries 14.49
Rashi Peripheral 344.50
Compuage Infocom 5.33
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.